Rgenta Therapeutics
Rgenta Therapeutics, Inc.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.
rgentatx.com · Woburn, MA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$41.9M of $130M
Filed2026-11-03
Days since filing10
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-19
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Hualin Simon XiExecutive Officer · Director
- Yichao FanDirector
- Debasish RoychowdhuryDirector
- Julia KaufmanDirector
- Sean ZhangDirector · Promoter
- Cillian KingDirector · Promoter
- James KasuboskiDirector
- Travis WagerExecutive Officer
- Weng ZhipingDirector
- Jeff GuckertExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$41.9M of $130M sold0.8 months since first sale
Prior raiseNot flaggedRaised $41.9M against a prior $8.9M$8.9M prior raise, filed 2022-02-07
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-11-040
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.